- Home
- PETS vs ELTX Comparison
PETS vs ELTX Comparison
Compare PETS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ELTX |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 185.4M |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PETS | ELTX |
|---|---|---|
| Price | $2.25 | $10.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 60.1K | ★ 132.9K |
| Earning Date | 06-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.92 | ★ 39.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.57 | $5.80 |
| 52 Week High | $4.32 | $14.93 |
Technical Indicators
Market Signals| Indicator | PETS | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 47.92 |
| Support Level | $2.19 | $9.97 |
| Resistance Level | $2.44 | $11.47 |
| Average True Range (ATR) | 0.09 | 0.87 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 16.63 | 28.81 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.